NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/09/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization833.36 mln
Float52.13 mln
Earnings Date08/06/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
37.67
Transformational upside
Relative Strength
95
/ 100
Top performer
Debt / Equity
0.01
Debt-free
ROE
-58.11
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Founded in 2017 and headquartered in Zug, Switzerland, Oculis Holding AG is a pharmaceutical company focused on developing new treatments for eye and neurological conditions. Its three main drug candidates target diabetic macular edema, dry eye disease, and a range of conditions involving nerve damage in the eye, including glaucoma and optic neuritis. Each candidate is currently being tested in mid-to-late stage clinical trials.
